Nuvectis Pharma, Inc. (NVCT)

Market Cap	98.54M
Revenue (ttm)	n/a
Net Income (ttm)	-19.37M
Shares Out	19.32M
EPS (ttm)	-1.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,874
Open	4.94
Previous Close	4.90
Day's Range	4.61 - 5.14
52-Week Range	4.61 - 12.10
Beta	0.40
Analysts	Strong Buy
Price Target	21.00 (+311.77%)
Earnings Date	Nov 5, 2024

About NVCT

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company’s lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2022
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCT
• Website: https://www.nuvectis.com

Analyst Forecast

According to one analyst, the rating for NVCT stock is "Strong Buy" and the 12-month stock price forecast is $21.0.

Price Target

$21.0

(311.77% upside)

Analyst Consensus: Strong Buy